| Autor: |
Uemoto, Yusuke, Taura, Kojiro, Kimura, Yusuke, Yoh, Tomoaki, Nishio, Takahiro, Koyama, Yukinori, Seo, Satoru, Okazaki, Kazuyuki, Nagao, Miki, Igarashi, Koji, Hatano, Etsuro |
| Zdroj: |
Journal of Hepato -- Biliary -- Pancreatic Sciences; Jun2023, Vol. 30 Issue 6, p825-833, 9p |
| Abstrakt: |
Background/Purpose: This study aimed to evaluate the usefulness of serum autotaxin, a novel liver fibrosis marker, for predicting post hepatectomy liver failure (PHLF) in patients undergoing hepatectomy for hepatocellular carcinoma (HCC). Methods: Autotaxin was measured in sera from 269 patients undergoing hepatectomy for HCC. Correlations between autotaxin level, liver fibrosis stage (METAVIR F0–F4), and PHLF, as assessed by the International Study Group of Liver Surgery criteria, were analyzed. Results: Median autotaxin concentrations correlated significantly with fibrosis stage (F0, 0.93; F1, 0.96; F2, 1.18; F3, 1.40; and F4, 1.47 mg/l; P <.0001). Autotaxin levels were significantly higher in female patients and hepatitis C virus antibody‐positive patients compared with male or antibody‐negative patients (P <.0001). PHLF grade ≥ B occurred in 25 patients (9.3%). A PHLF prediction model was constructed from four variables (autotaxin, resection rate, sex, and hepatitis C virus antibody positivity) and gave an area under the receiver operating characteristic curve of 0.8 (95% confidence interval [CI]: 0.69–0.87), which was superior to models based on ALPlat and resection rate (0.75, 95% CI: 0.64–0.83) or indocyanine green retention test and resection rate (0.72, 95% CI: 0.61–0.81). Conclusion: Serum autotaxin has utility for predicting liver fibrosis and PHLF in patients with HCC. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text